Pure Bioscience, Inc. financial data

Symbol
PURE on OTC
Location
771 Jamacha Road #512, El Cajon, CA
Fiscal year end
July 31
Latest financial report
Jun 16, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 95.5 % -55.6%
Quick Ratio 9.59 % -28.1%
Debt-to-equity -122 % +54.9%
Return On Equity 73.1 % -82%
Return On Assets -335 % -40.4%
Operating Margin -138 % +18.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares +0.03%
Common Stock, Shares, Outstanding 112M shares 0%
Entity Public Float 7.35M USD +49.7%
Common Stock, Value, Issued 1.12M USD 0%
Weighted Average Number of Shares Outstanding, Basic 112M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 112M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.91M USD -8.54%
Revenue from Contract with Customer, Excluding Assessed Tax 1.91M USD -8.56%
Research and Development Expense 312K USD +2.97%
Operating Income (Loss) -2.64M USD +25.1%
Nonoperating Income (Expense) -188K USD -70.9%
Net Income (Loss) Attributable to Parent -2.82M USD +22.1%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 540K USD +22.2%
Accounts Receivable, after Allowance for Credit Loss, Current 287K USD +22.7%
Inventory, Net 131K USD +77%
Assets, Current 1.05M USD +20.4%
Property, Plant and Equipment, Net 11K USD -78.4%
Assets 1.06M USD +14.9%
Accounts Payable, Current 799K USD +57.9%
Accrued Liabilities, Current 173K USD +8.13%
Liabilities, Current 972K USD +45.9%
Liabilities 5.87M USD +91.5%
Retained Earnings (Accumulated Deficit) -139M USD -2.08%
Stockholders' Equity Attributable to Parent -4.81M USD -124%
Liabilities and Equity 1.06M USD +14.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -503K USD -14.3%
Net Cash Provided by (Used in) Financing Activities 500K USD -36.3%
Common Stock, Shares Authorized 200M shares +33.3%
Common Stock, Shares, Issued 112M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3K USD -101%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 615K USD +19%
Deferred Tax Assets, Valuation Allowance 29.3M USD -3.33%
Deferred Tax Assets, Gross 29.3M USD -3.33%
Depreciation 37K USD
Property, Plant and Equipment, Gross 1.62M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD -4.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 133M USD +0.12%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 57K USD -28.8%
Interest Expense 111K USD +1133%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%